Comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".
作者信息
Shabil Muhammed, Bushi Ganesh, Rai Nishant, Abu Serhan Hashem
机构信息
University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
出版信息
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398870. doi: 10.1080/21645515.2024.2398870. Epub 2024 Oct 21.
Abstract
摘要
相似文献
1
Comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".评论：“替贝福司对转移性葡萄膜黑色素瘤患者的疗效和安全性：一项系统评价和荟萃分析”
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398870. doi: 10.1080/21645515.2024.2398870. Epub 2024 Oct 21.
2
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.特普替尼治疗转移性葡萄膜黑色素瘤患者的疗效和安全性：系统评价和荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2374647. doi: 10.1080/21645515.2024.2374647. Epub 2024 Jul 14.
3
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.替本福司他在晚期葡萄膜黑色素瘤中的应用：证明了 T 细胞受体疗法和双特异性药物在实体肿瘤中的疗效。
Expert Opin Biol Ther. 2022 Aug;22(8):997-1004. doi: 10.1080/14712598.2022.2031970. Epub 2022 Feb 2.
4
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.特必津治疗 HLA-A*02:01 阳性不可切除或转移性葡萄膜黑素瘤的成年患者。
Expert Rev Anticancer Ther. 2022 Oct;22(10):1017-1027. doi: 10.1080/14737140.2022.2124971. Epub 2022 Sep 19.
5
Response to comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".对关于“替贝福司对转移性葡萄膜黑色素瘤患者的疗效和安全性：一项系统评价和荟萃分析”评论的回应
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398874. doi: 10.1080/21645515.2024.2398874. Epub 2024 Oct 21.
6
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.靶向gp100和PRAME的T细胞接合双特异性抗体：从葡萄膜黑色素瘤到皮肤黑色素瘤的应用拓展
Pharmaceutics. 2024 Aug 6;16(8):1046. doi: 10.3390/pharmaceutics16081046.
7
Tebentafusp: First Approval.特泊替尼：首次获批。
Drugs. 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4.
8
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.转移性葡萄膜黑色素瘤患者使用替本福司他治疗的 3 年总生存率。
N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21.
9
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.特普替尼治疗转移性葡萄膜黑色素瘤的总生存获益。
N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.
10
Tebentafusp for the treatment of metastatic uveal melanoma.特贝妥珠单抗治疗转移性葡萄膜黑色素瘤。
Future Oncol. 2022 Apr;18(11):1303-1311. doi: 10.2217/fon-2021-1260. Epub 2022 Feb 17.
引用本文的文献
1
Prevalence of recurrent nerve injury among esophageal cancer patients undergoing esophagectomy: A systematic review and meta-analysis.食管癌切除术后患者喉返神经损伤的患病率：一项系统评价和荟萃分析。
Surg Open Sci. 2025 May 30;27:68-80. doi: 10.1016/j.sopen.2025.05.009. eCollection 2025 Sep.
2
Effect of SGLT-2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta-analysis and Bayesian sensitivity analysis.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者慢性阻塞性肺疾病急性加重的影响：一项荟萃分析和贝叶斯敏感性分析。
J Diabetes Investig. 2025 Sep;16(9):1670-1682. doi: 10.1111/jdi.70111. Epub 2025 Jul 2.
3
Prevalence and Determinants of Coronary Artery Calcification in Adults With Metabolic Syndrome: A Systematic Review and Meta-Analysis.代谢综合征成人冠状动脉钙化的患病率及影响因素：一项系统评价和荟萃分析
Clin Cardiol. 2025 Jun;48(6):e70156. doi: 10.1002/clc.70156.
4
Comment on: "Gastric adenocarcinoma and periodontal disease: a systematic review and meta-analysis".关于《胃腺癌与牙周病：系统评价与荟萃分析》的评论
Clinics (Sao Paulo). 2025 Mar 8;80:100596. doi: 10.1016/j.clinsp.2025.100596. eCollection 2025.
5
Comment on: "Prevalence and Influencing Factors of Malnutrition in Diabetic Patients: A Systematic Review and Meta-Analysis".关于《糖尿病患者营养不良的患病率及影响因素：系统评价与荟萃分析》的评论
J Diabetes. 2025 Mar;17(3):e70067. doi: 10.1111/1753-0407.70067.
6
Comment on: "whether temporal discounting is domain‑specific between health outcomes and money-a systematic review and meta‑analysis".关于《健康结果与金钱之间的时间贴现是否具有领域特异性：一项系统评价与荟萃分析》的评论
Int J Clin Pharm. 2025 Apr;47(2):584-585. doi: 10.1007/s11096-025-01877-4. Epub 2025 Feb 11.
7
Comment on: "Enhanced recovery after surgery (ERAS) in stoma reversal surgery: a systematic review and meta-analysis".关于《造口回纳手术中的加速康复外科（ERAS）：系统评价与荟萃分析》的评论
Updates Surg. 2025 Feb 5. doi: 10.1007/s13304-025-02126-z.
8
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.GLP-1 受体激动剂治疗患者肝细胞癌风险的系统评价和荟萃分析。
BMC Endocr Disord. 2024 Nov 18;24(1):246. doi: 10.1186/s12902-024-01775-2.
9
Response to comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis".对关于“替贝福司对转移性葡萄膜黑色素瘤患者的疗效和安全性：一项系统评价和荟萃分析”评论的回应
Hum Vaccin Immunother. 2024 Dec 31;20(1):2398874. doi: 10.1080/21645515.2024.2398874. Epub 2024 Oct 21.
本文引用的文献
1
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.特普替尼治疗转移性葡萄膜黑色素瘤患者的疗效和安全性：系统评价和荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2374647. doi: 10.1080/21645515.2024.2374647. Epub 2024 Jul 14.
2
Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance.好的或最佳实践声明：对 GRADE 指南的操作化和实施的建议。
BMJ Evid Based Med. 2023 Jun;28(3):189-196. doi: 10.1136/bmjebm-2022-111962. Epub 2022 Apr 15.
3
A new improved graphical and quantitative method for detecting bias in meta-analysis.一种新的改进的图形和定量方法，用于检测荟萃分析中的偏倚。
Int J Evid Based Healthc. 2018 Dec;16(4):195-203. doi: 10.1097/XEB.0000000000000141.
4
Plea for routinely presenting prediction intervals in meta-analysis.呼吁在荟萃分析中常规呈现预测区间。
BMJ Open. 2016 Jul 12;6(7):e010247. doi: 10.1136/bmjopen-2015-010247.
Zotero 插件